Navigation Links
Hologic Introduces Synthesized 2D Image Algorithm Designed to Eliminate the Need for a 2D Mammogram in a 2D plus 3D Tomosynthesis Exam
Date:11/27/2011

BEDFORD, Mass., Nov. 27, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the commercial release of its C-View synthesized 2D image reconstruction algorithm that eliminates the need for a conventional 2D mammogram as a component of a tomosynthesis (3D mammography) breast cancer screening exam. C-View software is approved for sale throughout the European Economic Area and in other countries recognizing the CE Mark.

For users of Hologic's 2D plus 3D tomosynthesis breast cancer screening system, C-View software creates a 2D image from a single tomosynthesis scan and eliminates the need for the acquisition of additional 2D exposures.

Dr. Stephen Rose, a board certified radiologist with Houston Breast Imaging, one of the first U.S. radiologists to adopt breast tomosynthesis, stated "Hologic's synthesized 2D image reconstruction algorithm is very impressive. C-View provides the information contained in a conventional 2D mammogram without the need for additional exposures while maintaining the superior clinical performance of Hologic's combo-mode (2D plus 3D) imaging."

Hologic is featuring the new algorithm along with the Company's Selenia Dimensions breast tomosynthesis system at the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the largest radiology show in the world, taking place at McCormick Place in Chicago November 26 through December 2.

Hologic is the global market leader in breast tomosynthesis (3D mammography) with its Selenia Dimensions platform. In Hologic's clinical studies, radiologists reading in combo-mode (2D plus 3D) compared to 2D mammography alone demonstrated superior clinical performance in ruling out breast cancer without recalling the patient for further study and the proportion of mammograms with cancer which were correctly diagnosed.

About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Hologic, C-View, Dimensions and Selenia are trademarks and/or registered trademarks of Hologic, Inc, and/or its subsidiaries in the United States and/or other countries.

Forward Looking Statement DisclaimerThis News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance that the C-View synthesized 2D image reconstruction algorithm when used with a Selenia Dimensions breast tomosynthesis system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.Contacts:Olga Karagiannis

 

Jim Culley, PhDCorporate Marketing

 

Corporate MarketingHologic, Inc.

 

Hologic, Inc.Tel: 781.761.7069

Olga.karagiannis@hologic.com

 

Tel: 781.999.7583

Jim.culley@hologic.com


'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):